New research developments demonstrate how gut bacteria influence brain health and learning ability in rats with chronic liver disease.
Key Findings:
- The antibiotic rifaximin reshapes the gut microbiome to improve cognitive function in liver disease.
- Beneficial bacteria are linked to enhanced learning and neurotransmitter balance.
- Short-chain fatty acid balance emerges as a critical marker of gut-brain health.
- This research offers new therapeutic strategies for hepatic encephalopathy.
A new study published in Scientific Reports shows an association between treatment with rifaximin, a gut-targeted antibiotic, and improved cognitive function as well as a reduced risk of hepatic encephalopathy–a neuropsychiatric disorder that occurs when the liver is unable to properly process toxins, leading to their accumulation in the brain–by influencing the gut-brain axis in rats with liver injury. This research provides crucial insights into the mechanisms behind cognitive impairment in liver disease and offers promising therapeutic avenues.
Understanding Hepatic Encephalopathy and Cognitive Decline
Hepatic encephalopathy is a complex neuropsychiatric syndrome affecting patients with liver cirrhosis, ranging from mild symptoms to life-threatening conditions, with patients experiencing mild cognitive impairment, attention deficits, and psychomotor slowing. The condition poses major health, social, and economic challenges, making effective treatments critical.
How Rifaximin Transforms the Gut Microbiome
The research team, led by Llansola and colleagues, used a rat model with carbon tetrachloride-induced liver injury to investigate rifaximin’s effects. Their findings revealed remarkable differences in how the antibiotic affects healthy versus diseased states.
Differential Effects on Microbial Diversity
Rifaximin altered microbiota diversity and composition, increasing diversity the diversity of gut bacterial species in liver-injured rats but reducing diversity in healthy rats. This selective action suggests the antibiotic’s therapeutic effect depends on the existing inflammatory environment.
In healthy rats, rifaximin reduced diversity by affecting 12 bacterial species, primarily targeting producers of short-chain fatty acids (compounds produced from the fermentation of dietary fiber). However, in rats with liver injury, the antibiotic treatment had positive and negative associations with 68 species, showing a more complex effect on bacterial group changes.
Key Bacterial Players in Brain Health
The study identified specific bacterial families critical to cognitive improvement:
Rifaximin influenced microbiota interactions with neurotransmission alterations, where bacterial species Dorea, Lachnospiraceae A2, and possibly Erysipelotricaceae might be important contributors. These bacterial groups are known producers of short-chain fatty acids and are involved in metabolizing neurotransmitter precursors.
The Neurotransmitter Connection
Previous studies using this model reported that rifaximin treatment reduced peripheral inflammation and neuroinflammation, improving motor and cognitive function by modulating GABA transporter membrane expression, important in fine-tuning synaptic transmission, in a brain region called the cerebellum and normalizing glutamate NMDA receptor subunit expression, crucial for memory formation, in a brain region called the hippocampus.
The current research reveals that these beneficial effects occur through microbiome modulation, with certain bacterial families showing positive associations with cognitive function and neurotransmitter receptor expression critical for spatial learning and memory.
Mechanisms of Cognitive Improvement
The research unveils a multi-step pathway connecting gut bacteria to brain function:
- Inflammation Reduction: Rifaximin reduces peripheral inflammatory markers and prevents immune cell infiltration into brain regions.
- Bacterial Selection: The antibiotic inhibits harmful bacteria while promoting beneficial species.
- Metabolic Shift: Changes in bacterial composition alter short-chain fatty acid production and neurotransmitter metabolism.
- Receptor Normalization: An improved gut environment leads to normalized expression of critical brain receptors.
- Cognitive Recovery: Restored neurotransmission improves spatial learning and memory.
Clinical Implications for Hepatic Encephalopathy
These findings have significant implications for treating cognitive impairment in liver disease patients. Treatment with rifaximin is effective in restoring cognitive function in cirrhotic patients with minimal hepatic encephalopathy and reduces the risk of recurrent hepatic encephalopathy, which was associated with a shift in peripheral inflammation.
The research suggests that microbiome-targeted interventions could provide new therapeutic strategies for:
- Cognitive impairment in early-stage liver disease
- Preventing progression to severe hepatic encephalopathy
- Reducing neuroinflammation in liver disease
Future Research Directions
This study opens several avenues for future investigation:
- Precision Microbiome Medicine: Identifying specific bacterial strains that could be used as probiotics
- Biomarker Development: Using short-chain fatty acid balance as a diagnostic tool for gut-brain axis dysfunction
- Therapeutic Optimization: Determining optimal rifaximin dosing and treatment duration
- Mechanism Validation: Confirming the causal relationships between specific bacteria and cognitive improvements
Conclusion
This landmark study demonstrates that the gut-brain axis plays a central role in cognitive complications of liver disease. By revealing how rifaximin selectively promotes beneficial bacteria while suppressing harmful species, researchers have identified potential new targets for therapeutic intervention.
The introduction of the short-chain fatty acid balance concept provides a novel framework for understanding gut health and its connection to brain function. As research continues to unveil the intricate connections between the gut microbiome and neurological health, microbiome-targeted therapies may emerge as powerful tools for treating cognitive disorders associated with various diseases.
Story Source
Giner-Pérez L, Jarquín-Díaz VH, Leone P, Giménez-Garzó C, Mincheva G, Mira Á, Forslund-Startceva SK, Rubio T, Felipo V, Pérez-Martínez G, Llansola M. Rifaximin-induced changes in the gut microbiome associated to improvement of neurotransmission alterations and learning in rats with chronic liver disease. Sci Rep. 2025 Oct 2;15(1):34382. doi: 10.1038/s41598-025-17229-1. PMID: 41038926; PMCID: PMC12491630.